A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Business description not available.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -6.3M | -6.3M | -9.2M | -43M | -31M | -20M |
| EPS | $-0.15 | $-0.15 | $-0.37 | $-1.91 | $0.00 | $0.00 |
| Free Cash Flow | -6.1M | -6.1M | -17M | -30M | -32M | -32M |
| ROIC | -46.6% | -160.6% | -99.9% | -163.7% | -84.4% | -34.4% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 12.86 | 1.12 | 1.15 | 0.73 | 0.75 |
| Dividends/Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | -6.3M | -6.3M | -9.2M | -43M | -31M | -20M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -1139.7% | -1139.7% | -134.0% | -948.2% | -85.5% | -55.5% |
| Shares Outstanding | 42M | 42M | 25M | 23M | 0M | 0M |
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | -25M | -25M | -20M | -5.0M | -3.5M | -3.5M |
| SG&A | -11M | -12M | -11M | -6.5M | -3.5M | -3.5M |
| EBIT | -20M | -31M | -43M | -9.2M | -6.3M | -6.3M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -20M | -31M | -43M | -9.2M | -6.3M | -6.3M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||
| ROIC | -34.4% | -84.4% | -163.7% | -99.9% | -160.6% | -46.6% |
| ROE | -55.5% | -85.5% | -948.2% | -134.0% | -1139.7% | -1139.7% |
| ROA | -26.0% | -33.2% | -207.6% | -51.9% | -58.7% | -58.7% |
| Cash Flow | ||||||
| Op. Cash Flow | -32M | -31M | -29M | -17M | -6.1M | -6.1M |
| Free Cash Flow | -32M | -32M | -30M | -17M | -6.1M | -6.1M |
| Owner Earnings | -35M | -34M | -31M | -18M | -6.2M | -6.2M |
| CapEx | 172K | 391K | 130K | 976K | 0 | 0 |
| Maint. CapEx | 0 | 0 | 0 | 0 | 0 | 0 |
| Growth CapEx | N/A | N/A | N/A | N/A | N/A | 0 |
| D&A | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | 3.2M | 2.6M | 1.7M | 1.0M | 39K | 39K |
| Debt Repayment | 493K | 330K | 242K | 347K | 0 | 0 |
| Balance Sheet | ||||||
| Net Debt | 6.9M | -8.9M | -7.9M | 46K | 2.6M | -4.5M |
| Cash & Equiv. | 20M | 35M | 13M | 7.6M | 4.5M | 4.5M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.75 | 0.73 | 1.15 | 1.12 | 12.86 | 0.00 |
| Interest Coverage | -39.1 | -103.5 | -206.3 | -100.7 | -49.2 | -49.2 |
| Equity | 36M | 37M | 4.5M | 6.8M | 552K | 552K |
| Total Assets | 76M | 94M | 21M | 18M | 11M | 11M |
| Total Liabilities | 40M | 58M | 16M | 11M | 10M | 10M |
| Intangibles | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | -325M | -365M | -368M | -389M | -393M | -393M |
| Working Capital | 9.0M | 24M | 4.6M | 8.9M | 4.0M | 4.0M |
| Current Assets | 23M | 40M | 16M | 12M | 7.0M | 7.0M |
| Current Liabilities | 14M | 16M | 11M | 3.2M | 3.1M | 3.1M |
| Per Share Data | ||||||
| EPS | 0.00 | 0.00 | -1.91 | -0.37 | -0.15 | -0.15 |
| Owner EPS | N/A | N/A | -1.38 | -0.71 | -0.15 | -0.15 |
| Book Value | 0.00 | 0.00 | 0.20 | 0.28 | 0.01 | 0.01 |
| Cash Flow/Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.15 |
| Dividends/Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Shares Out. | 0.0M | 0.0M | 22.6M | 24.8M | 41.6M | 41.6M |
| Valuation | ||||||
| P/E Ratio | N/A | N/A | -0.3 | -1.1 | -4.8 | -2.1 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | 2.7 | 1.5 | 54.3 | 24.5 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | N/A | -243.7% | -175.8% | -20.5% | -45.4% |
| Market Cap | 0 | 0 | 12M | 9.9M | 30M | 14M |
| Avg. Price | 9.58 | 5.69 | 1.99 | 0.79 | 0.40 | 0.32 |
| Year-End Price | 8.07 | 4.02 | 0.54 | 0.40 | 0.72 | 0.32 |
CELYAD ONCOLOGY passes 0 of 9 quality checks, indicating weak fundamentals.
CELYAD ONCOLOGY (CYAD-BR) has a 5-year average return on invested capital (ROIC) of -108.6%. This is below average and may indicate limited pricing power.
CELYAD ONCOLOGY (CYAD-BR) has a market capitalization of $14M. It is classified as a small-cap stock.
CELYAD ONCOLOGY (CYAD-BR) does not currently pay a regular dividend.
CELYAD ONCOLOGY (CYAD-BR) generated $-6 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
CELYAD ONCOLOGY (CYAD-BR) has a debt-to-equity ratio of 12.86. This indicates higher leverage, which may increase financial risk.
CELYAD ONCOLOGY (CYAD-BR) reported earnings per share (EPS) of $-0.15 in its most recent fiscal year.
CELYAD ONCOLOGY (CYAD-BR) has a return on equity (ROE) of -1139.7%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 5 years of financial data for CELYAD ONCOLOGY (CYAD-BR), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
CELYAD ONCOLOGY (CYAD-BR) has a book value per share of $0.01, based on its most recent annual SEC filing.